The Tanzania Neurology Clinical Trials market is projected to grow from $2.09 Mn in 2022 to $3.44 Mn by 2030, registering a CAGR of 6.4% during the forecast period of 2022 - 2030. The market will be driven by investment in infrastructure, resources, and training for healthcare professionals, as well as collaboration between local and international stakeholders. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Sanofi S.A., AstraZeneca & GlaxoSmithKline.
The South Africa Neurology Clinical Trials market is projected to grow from $34 Mn in 2022 to $57.2 Mn by 2030, registering a CAGR of 6.73% during the forecast period of 2022 - 2030. The market will be driven by the availability of a diverse population, a large number of well-trained healthcare professionals and modern medical healthcare facilities. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Eli Lilly and Company & Biovac.
The Romania Neurology Clinical Trials market is projected to grow from $15.2 Mn in 2022 to $23.7 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022 - 2030. The market will be driven by collaborations with international research institutions and improved funding for clinical research. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen Inc., Pfizer Inc. & Novartis AG.
The Poland Neurology Clinical Trials market is projected to grow from $30.3 Mn in 2022 to $48.2 Mn by 2030, registering a CAGR of 5.95% during the forecast period of 2022 - 2030. The market will be driven by a skilled workforce, a supportive regulatory framework, and a relatively low cost of conducting research. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen Inc., Pfizer Inc. & Novartis AG.
The Nigeria Neurology Clinical Trials market is projected to grow from $4.71 Mn in 2022 to $7.79 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological disorders and the development of a framework for aiding more clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis AG & Merck & Co.
The Netherlands Neurology Clinical Trials market is projected to grow from $13.6 Mn in 2022 to $21.7 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the modern healthcare infrastructure and an innovative & collaborative research environment. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen Netherlands BV, Roche Holding AG & Johnson & Johnson.
The Kenya Neurology Clinical Trials market is projected to grow from $3.66 Mn in 2022 to $6.1 Mn by 2030, registering a CAGR of 6.6% during the forecast period of 2022 - 2030. The market will be driven by investments in healthcare infrastructure by the Kenyan government and a favourable regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include Merck & Co., Inc., Novartis International AG, and Roche Holding AG.
The Belgium Neurology Clinical Trials market is projected to grow from $11.5 Mn in 2022 to $17.7 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022 - 2030. The market will be driven by the rising prevalence of neurological disorders and a favourable regulatory environment. The market is segmented by phase, by study design & by indication. Some of the major players include UCB, Biogen Inc & Icometrix.
The Vietnam Neurology Clinical Trials market is projected to grow from $26.2 Mn in 2022 to $40.8 Mn by 2030, registering a CAGR of 5.73% during the forecast period of 2022 - 2030. The market will be driven by the rising frequency of neurological illnesses such as Alzheimer's, Parkinson's, and stroke along with improving healthcare infrastructure in Vietnam. The market is segmented by phase, by study design & by indication. Some of the major players include Biogen, Pfizer Inc. & Vietnam Pharmaceutical Corporation.
The UK Neurology Clinical Trials market is projected to grow from $342.2 Mn in 2022 to $451.4 Mn by 2030, registering a CAGR of 3.52% during the forecast period of 2022 - 2030. The market will be driven by increasing funding and assistance from institutions such as the NIHR as well as greater awareness and understanding of neurological disorders. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Biogen Inc & Cambridge Cognition Holdings PLC.
The UAE Neurology Clinical Trials market is projected to grow from $26.2 Mn in 2022 to $43.3 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022 - 2030. The market will be driven by the modern healthcare infrastructure and a favourable regulatory environment that encourages investment in clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Pfizer, and Biogen.
The Turkey Neurology Clinical Trials market is projected to grow from $41.8 Mn in 2022 to $66.7 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the rising frequency of neurological illnesses such as Alzheimer's, Parkinson's, and stroke and rising investment in research facilities. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis AG & Abdi İbrahim.
The Thailand Neurology Clinical Trials market is projected to grow from $6.28 Mn in 2022 to $9.88 Mn by 2030, registering a CAGR of 5.84% during the forecast period of 2022 - 2030. The market will be driven by the country's favourable regulatory environment, big patient pool, and highly qualified medical professionals. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Pfizer Inc. & Siam Bioscience Co., Ltd.
The Spain Neurology Clinical Trials market is projected to grow from $100.9 Mn in 2022 to $143.5 Mn by 2030, registering a CAGR of 4.5% during the forecast period of 2022 - 2030. The market will be driven by well-established infrastructure, skilled researchers, and access to a big patient population. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc, Grifols, S.A. & Almirall, S.A.
The South Korea Neurology Clinical Trials market is projected to grow from $76.4 Mn in 2022 to $126.5 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022 - 2030. The market will be driven by the supportive regulatory environment and increasing interest from pharmaceutical companies investing in neurology clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Hoffmann-La Roche, Biogen & Chong Kun Dang Pharmaceutical.
The Singapore Neurology Clinical Trials market is projected to grow from $6.28 Mn in 2022 to $10.08 Mn by 2030, registering a CAGR of 6.1% during the forecast period of 2022 - 2030. The market will be driven by investments in clinical research and fostering collaborations between researchers, healthcare professionals, and industry partners. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Biogen & Invitrocue Pte Ltd.
The Saudi Arabia Neurology Clinical Trials market is projected to grow from $88.9 Mn in 2022 to $152.8 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological disorders, and increasing investment in healthcare infrastructure. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis AG & Tabuk Pharmaceuticals.
The Philippines Neurology Clinical Trials market is projected to grow from $11.5 Mn in 2022 to $18.3 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the country's growing clinical trial industry and a large pool of potential study participants. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Pfizer & Philippine Pharma Solutions, Inc.
The Mexico Neurology Clinical Trials market is projected to grow from $78.5 Mn in 2022 to $122.7 Mn by 2030, registering a CAGR of 5.75% during the forecast period of 2022 - 2030. The market will be driven by the rising frequency of neurological illnesses and increased investments in R&D by pharmaceutical companies. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis AG & Laboratorios Silanes.
The Global clinical trial patient recruitment services market is projected to grow from $ 0.84 Mn in 2022 to $1.56 Bn by 2030, registering a CAGR of 8% during the forecast period of 2022-30. The Global clinical trial patient recruitment services market is a rapidly growing market that provides services to support the recruitment of patients for clinical trials. Some key players in the global clinical trial patient recruitment services market include IQVIA, Parexel International, PRA Health Sciences, Syneos Health, and WCG Clinical. Other important players include ICON plc, Medpace, Charles River Laboratories, and Premier Research.
The Malaysia Neurology Clinical Trials market is projected to grow from $8.41 Mn in 2022 to $13.1 Mn by 2030, registering a CAGR of 5.7% during the forecast period of 2022 - 2030. The market will be driven by a well-developed healthcare infrastructure and a large pool of potential study participants. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis AG & Merck Sharp & Dohme Malaysia.
The Japan Neurology Clinical Trials market is projected to grow from $325.1 Mn in 2022 to $518.1 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological diseases and a robust healthcare system. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Pfizer, Eisai Co., Ltd & Daiichi Sankyo.
The Italy Neurology Clinical Trials market is projected to grow from $125.5 Mn in 2022 to $185.5 Mn by 2030, registering a CAGR of 5% during the forecast period of 2022 - 2030. The market will be driven by the rising demand for novel therapies for neurological disorders and the supportive regulatory climate in Italy. The market is segmented by phase, by study design & by indication. Some of the major players include AstraZeneca, Chiesi Farmaceutici & Menarini.
The Indonesia Neurology Clinical Trials market is projected to grow from $31.4 Mn in 2022 to $48.2 Mn by 2030, registering a CAGR of 5.5% during the forecast period of 2022 - 2030. The market will be driven by the rising investments by global pharmaceutical companies in Indonesia due to reduced operating costs and improved healthcare infrastructure. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Roche & PT Dexa Medica.
The India Neurology Clinical Trials market is projected to grow from $95.1 Mn in 2022 to $182.7 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological disorders and the low cost of conducting clinical trials in India. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Sun Pharmaceutical Industries & Cadila Healthcare.